The $60 Billion AI Heist: Why SpaceX Just Locked Up Cursor—and How Andreessen and Thrive Are Cashing In

 

 The $60 Billion AI Heist: Why SpaceX Just Locked Up Cursor—and How Andreessen and Thrive Are Cashing In

**Subtitle:** *In a stunning pre-IPO move, Elon Musk’s SpaceX secured an option to acquire AI coding phenom Cursor for $60 billion. If the deal closes, early backers Andreessen Horowitz and Thrive Capital could walk away with a combined $10.2 billion payday—or face a high-stakes “test drive” with a $10 billion breakup fee.*

**Reading Time:** 8 Minutes | **Category:** Artificial Intelligence & Investing

## Introduction: The Deal That Rewrote the AI Playbook

On April 21, 2026, Elon Musk did something he has done many times before: he broke the internet.

SpaceX—the rocket, satellite, and now AI giant—announced an agreement giving it the right to acquire the AI startup Cursor for a staggering $60 billion later this year, or alternatively pay $10 billion for the privilege of working together if the deal doesn't close.

This was not a traditional acquisition. It was something far more clever. A "call option" on the hottest AI startup on the planet, timed precisely to SpaceX's own impending IPO and designed to lock up Cursor's talent, product, and—most critically—its developer ecosystem, without triggering the antitrust scrutiny a cash purchase would invite.

Cursor, for the uninitiated, is the "vibe coding" platform that has become indispensable to millions of software developers. Founded in 2022 by four MIT students who never finished their degrees, the company has rocketed to a valuation of over $50 billion in just four years. Its AI assistant helps programmers write, debug, and refactor code at lightning speed, and its annualized revenue has already surpassed $20 billion.

Now, Musk has effectively placed a $60 billion bet that Cursor is the missing piece in his AI puzzle—a puzzle that includes xAI, Grok, and the Colossus supercomputer.

For the venture capital firms that backed Cursor early—notably Andreessen Horowitz (a16z) and Thrive Capital—the deal represents a potential payoff of historic proportions. With stakes estimated at roughly 10% and 7% respectively, they could be looking at $6 billion and $4.2 billion exits if the acquisition goes through.

But here is the twist: the deal is not done. Not yet. Musk has effectively put Cursor on a high-stakes "test drive" until the end of 2026. If Cursor hits its ambitious growth targets, he buys it. If it stumbles, he pays $10 billion for the partnership and walks away with its technology anyway.

In this deep-dive, we will break down the unprecedented deal structure, reveal exactly how much Andreessen and Thrive stand to make, and explain why Musk is willing to spend $60 billion on a four-year-old startup that is still losing money.

## Part 1: The Deal That Defied Gravity—How the $60 Billion Option Works

Let's start with the structure, because it is unlike anything we have seen in Silicon Valley.

SpaceX announced that it had secured a "right to acquire" Cursor later in 2026 for $60 billion. That is an options contract. If SpaceX decides to pull the trigger, it buys the company at that price. If it decides not to, it still must pay Cursor $10 billion as a "breakup fee" or "partnership payment".

The deal is not an immediate acquisition. According to sources familiar with the matter, SpaceX is delaying the actual buyout until after its planned IPO this summer. Why? Because a $60 billion transaction would require updating the company's confidential financial filings, potentially delaying the public offering. By structuring the deal as an option, SpaceX keeps the IPO on track while locking up Cursor's future.

The economics of the arrangement are fascinating:

| Component | Details |

| :--- | :--- |

| **Option Exercise Price** | $60 billion |

| **Breakup Fee / Partnership Payment** | $10 billion (if SpaceX walks away) |

| **Cursor Valuation (Recent Round)** | $50+ billion (paused) |

| **SpaceX IPO Target Valuation** | $1.75 trillion |

| **SpaceX Planned Fundraise** | Up to $75 billion |

*Sources: DoNews, GuruFocus, Bloomberg*

Just hours before SpaceX announced the deal, Cursor was on the verge of closing a $2 billion funding round led by Andreessen Horowitz and Thrive Capital at a valuation exceeding $50 billion. That round is now effectively dead. Why would Cursor take private money when SpaceX is offering a guaranteed exit at a premium?

The answer is that Cursor didn't have a choice. Once SpaceX made its move, the funding round evaporated. Investors want a path to liquidity. Musk just handed them one.

## Part 2: The Windfall—How Much Andreessen and Thrive Will (Literally) Cash Out

Let us talk about the money, because it is historic.

Andreessen Horowitz (a16z) led Cursor's Series A in August 2024 at a valuation of just $400 million. At the time, Cursor was a promising but unproven AI coding tool. The software worked well, but it was not clear whether developers would pay for it.

They paid. And then they paid more.

By November 2025, Cursor had raised a $2.3 billion Series D at a $29.3 billion valuation. The company's annualized revenue had exploded to $20 billion by February 2026. Andreessen had participated in every round, increasing its stake.

According to an analysis by GuruFocus, a16z is now the largest outside shareholder in Cursor, holding approximately 10% of the company. Thrive Capital follows closely with about 7%.

Here is how the math works if the $60 billion deal closes:

| Investor | Estimated Stake | Value at $60 Billion Exit | Potential Profit (Est.) |

| :--- | :--- | :--- | :--- |

| **Andreessen Horowitz** | ~10% | $6 billion | ~$5.6 billion |

| **Thrive Capital** | ~7% | $4.2 billion | ~$3.9 billion |

| **DST Global** | ~3% | $1.8 billion | — |

| **Accel** | ~2% | $1.2 billion | — |

| **Benchmark** | ~1-2% | $600 million - $1.2 billion | — |

| **Neo** | ~1-2% | $600 million - $1.2 billion | — |

*Source: GuruFocus*

These numbers are staggering. Andreessen Horowitz's $6 billion exit would be one of the largest venture capital returns in history—ranking alongside Sequoia's Google investment and SoftBank's Alibaba bet.

But—and this is a critical but—the deal also creates a massive tax headache. Cursor is structured as a C-corporation. If SpaceX acquires it for $60 billion, the founders and employees will face an enormous tax liability on their shares. That is one reason why the $10 billion "partnership" option might actually be more appealing to some early shareholders. It provides a liquidity event without a full acquisition, allowing for a slower, more tax-efficient exit.

And here is the twist: The venture capital firms are not just passive observers. They are co-leading the very funding round that SpaceX just effectively killed. That gives them a front-row seat to the negotiations—and significant leverage. They can push Cursor to hit its growth targets, or they can negotiate a better deal if the acquisition falls through.

As one analyst put it: *"This isn't just a partnership; it's a high-stakes test drive with a $10 billion deposit"{citation:10}.*

## Part 3: The Strategic Rationale—Why Musk Needs Cursor (And Why Cursor Needs Him)

To understand why Musk is willing to write a check that could buy a small country, you have to understand the state of the AI wars in 2026.

### The AI Coding Race

The battle for AI coding supremacy has become the most intense front in the larger AI war. Why? Because coders are the highest-value users of AI tools. They pay subscriptions. They build ecosystems. And they train the next generation of models simply by using them.

Here is where the major players stand:

| Player | Flagship AI Coding Tool | Estimated Annualized Revenue (Coding) | Key Differentiator |

| :--- | :--- | :--- | :--- |

| **Anthropic** | Claude Code | $30+ billion | Enterprise developer adoption |

| **OpenAI** | Codex | $20+ billion | Integration with ChatGPT ecosystem |

| **Cursor** | Composer | $20-60 billion (target) | Standalone IDE loyalty |

| **Google** | Antigravity | ~$5 billion (est.) | Deep Gemini integration |

| **xAI (Grok)** | None (in development) | Minimal | — |

*Source: 36Kr, internal company data estimates*

The data tells a clear story. Anthropic's Claude Code is the current leader, with an estimated $300 billion run-rate. OpenAI's Codex is close behind. Google's Antigravity is struggling despite a "talent acquisition" strategy that absorbed Windsurf.

And xAI, Musk's own AI company, is behind. Way behind.

In March 2026, Musk publicly admitted that xAI was "currently behind in coding" compared to its rivals. He ordered a round of layoffs. He vowed to "rebuild the company from the ground up".

Enter Cursor.

### The Three Things Cursor Brings to Musk

Cursor offers Musk three things he desperately needs:

**1. The Developer Entry Point**

Cursor has over 1 million paying users and an estimated 100,000 daily active developers. These are the people who build the software that runs the world. They are the influencers of the developer community. If Grok can win their loyalty, it wins the coding war.

**2. The Product Intelligence**

Cursor's product team has spent years learning how to make AI actually useful for software engineering. They have iterated on features, optimized for developer workflows, and built a brand that developers trust. xAI, by contrast, has been focused on foundational model research—important, but not sufficient to win the end-user battle.

**3. The Talent**

In March 2026, before the deal was announced, two of Cursor's most senior product engineering leads—Andrew Milich and Jason Ginsberg—quietly left to join xAI. They now report directly to Musk. This was not a coincidence. It was a pre-acquisition talent raid.

Cursor's president, Oskar Schulz, acknowledged the synergy: "The SpaceX team has an enormous amount of compute and we think together we can scale up our model efforts and we're really excited about it".

## Part 4: The Colossus Factor—Why Compute Is the New Currency

Finally, we come to the Colossus supercomputer.

xAI has spent billions building a massive GPU cluster in Memphis, Tennessee, known as **Colossus**. According to SpaceX, it has the compute power equivalent of **one million Nvidia H100 GPUs**.

That is a staggering amount of compute. But there is a problem: xAI's utilization rate is only about 11%, compared to an industry average of 35-45%. In plain English, Musk has bought a Ferrari and is driving it to the grocery store.

### The Compute Bottleneck at Cursor

Cursor has the opposite problem. It has massive demand for compute—its models need to be trained and its inference engines need to run—but it has been "bottlenecked" by access to GPUs at reasonable prices. The company has been renting compute from cloud providers and paying premium prices.

The SpaceX deal solves both problems. Cursor gets access to Colossus at a deep discount (or potentially for free as part of the partnership). SpaceX gets a "anchor tenant" for its underutilized compute resources, turning a cost center into a revenue stream.

This is the genius of the deal structure. Musk is not just buying a company. He is buying a **customer** for his compute. Whether the acquisition happens or not, SpaceX will be selling GPU capacity to Cursor. If the acquisition happens, Musk gets the entire company. If it does not, he gets a $10 billion partnership and a long-term compute client.

Either way, Musk wins.

### The "Compute-as-Capital" Model

This deal represents a new paradigm in Silicon Valley: **using compute as capital**.

In the past, startups pitched venture capitalists on ideas. The VCs provided money. The startups used the money to buy compute from AWS or Google Cloud.

Now, Musk is bypassing the money entirely. He is offering compute directly in exchange for equity and strategic control.

This is a game-changer. If it works, other compute-rich companies (Microsoft, Google, Meta) will replicate the model. Startups will no longer raise money to buy compute; they will raise compute directly from providers, with the providers taking equity stakes.

For Cursor, this is a lifeline. The company needs compute to train its next-generation model, Composer 2.5. Without Colossus, it would have to raise billions more in venture funding—diluting its founders and early investors. With Colossus, it gets the compute it needs without giving up more equity than it already has (at least not yet).

## Frequently Asked Questions (FAQ)

**Q: What exactly did SpaceX announce?**

**A:** SpaceX announced that it has secured the right to acquire Cursor for $60 billion later this year. If it chooses not to acquire, it will pay Cursor $10 billion for a partnership. The structure is an options contract tied to SpaceX's upcoming IPO.

**Q: How much will Andreessen Horowitz and Thrive Capital make if the deal closes?**

**A:** Based on their estimated stakes—approximately 10% for Andreessen and 7% for Thrive—a $60 billion acquisition would value their stakes at $6 billion and $4.2 billion, respectively. Their original investments were in the hundreds of millions, so the profits would be in the billions.

**Q: Why is SpaceX delaying the acquisition?**

**A:** To avoid updating its confidential IPO filing. A $60 billion transaction would require detailed financial disclosures, potentially delaying or complicating the public offering. By structuring the deal as an option to be exercised after the IPO, SpaceX keeps its listing on track.

**Q: What is Cursor and why is it worth so much?**

**A:** Cursor is an AI-powered coding assistant that helps developers write, debug, and refactor code. It has over 1 million paying users and annualized revenue of approximately $20 billion. The company's growth rate and strategic importance in the AI coding race justify its multi-billion dollar valuation.

**Q: What is the Colossus supercomputer?**

**A:** Colossus is xAI's GPU cluster in Memphis, Tennessee. According to SpaceX, it has the compute power equivalent of one million Nvidia H100 GPUs. The cluster is currently underutilized, which is why SpaceX is eager to rent capacity to Cursor.

**Q: Is Cursor still raising money?**

**A:** No. The planned $2 billion funding round at a $50+ billion valuation has been paused following the SpaceX announcement. Cursor no longer needs the capital because it will get compute from Colossus instead.

**Q: What happens if the acquisition falls through?**

**A:** SpaceX will pay Cursor $10 billion over time as a "partnership payment." The two companies will continue working together, with Cursor using Colossus compute and SpaceX benefiting from Cursor's technology. Cursor would remain independent.

**Q: Is this a good deal for Cursor's founders?**

**A:** It depends on the terms they negotiated. The $60 billion price tag is a premium over the $50+ billion valuation they were seeking in their last funding round. However, the founders will face massive tax liabilities on their shares if the deal closes, and they will lose their independence as a standalone company.

## Conclusion: The AI Bonanza Is Just Getting Started

We started this article with a stunning number: $60 billion.

That is the price Elon Musk is willing to pay for a four-year-old startup that helps developers type faster.

But the number is not really about Cursor. It is about what Cursor represents.

In the AI era, the ability to write code is the ability to build everything. And the ability to provide the compute that makes that possible is the most valuable asset on Earth.

Musk has both—Cursor for the code, Colossus for the compute. And he has structured the deal so that he wins whether the acquisition happens or not.

For Andreessen Horowitz and Thrive Capital, the bet paid off. Their early, patient investments in a risky AI startup have turned into billions. They took the risk when others said "AI coding is a niche." They were right.

But here is the question that matters for the rest of us: **Is this the peak?**

AI valuations have exploded. Cursor is profitable in terms of revenue, but it is not cash-flow positive—it burns money on compute. The $60 billion price tag assumes that the company can triple its revenue again by the end of the year.

That is a big assumption. And if it fails, Musk will pay the $10 billion partnership fee and walk away.

Either way, the AI bonanza is just getting started. The winners are being chosen now. And the stakes have never been higher.

**The Bottom Line:** SpaceX just placed a $60 billion bet that AI coding is the future. Andreessen and Thrive just made billions. And the rest of us are watching the richest man in the world play chess while everyone else is still learning the rules.

---

**#SpaceX #Cursor #ElonMusk #AI #ArtificialIntelligence #AndreessenHorowitz #ThriveCapital #Merger #IPO #VentureCapital**

---

*Disclaimer: This article is for informational purposes only. It does not constitute financial or investment advice. Merger and acquisition terms are subject to change. Always consult a licensed professional before making investment decisions.*

The $4 billion blow: American Airlines slashes 2026 profit outlook as jet fuel crisis burns through cash

 

 The $4 billion blow: American Airlines slashes 2026 profit outlook as jet fuel crisis burns through cash

**Subtitle:** *From record revenue to a brutal reality check—how the Iran war, a $382 million quarterly loss, and a potential Alaska partnership are reshaping the airline's turbulent future.*

**Reading Time:** 8 Minutes | **Category:** Economy & Markets

## Introduction: The Optimism That Crashed Before Takeoff

Just a few weeks ago, things were finally looking up for American Airlines. The post-pandemic travel boom was in full swing. Passengers were packing planes. Revenue was climbing. And on April 14, when news of a potential ceasefire between the U.S. and Iran broke, American's stock soared nearly 9% in a single day. Investors allowed themselves to believe that the worst of the fuel crisis might already be behind them.

Then Thursday arrived.

American Airlines dropped a financial report card that wiped that optimism off the board. The numbers told a story of a company caught between two immovable forces: soaring demand and a $4 billion fuel bill.

Here is what the airline reported for the first three months of 2026:

| Metric | Q1 2026 Actual | Wall Street Expected | Q1 2025 |

| :--- | :--- | :--- | :--- |

| **Net Loss** | $382 million | — | $473 million |

| **Adjusted Loss Per Share** | $0.40 | $0.47 loss | — |

| **Total Revenue** | $13.91 billion | $13.79 billion | $12.55 billion |

| **Revenue Growth (YoY)** | +10.8% | — | — |

*Sources: CNBC, American Airlines Investor Relations, Reuters*

The headline looks like a mixed bag, and in some ways it is. Revenue hit an all-time high for any first quarter in the company's history. More people are flying than ever before, and they are paying more to do it.

But beneath that shiny revenue number lurks a brutal reality. Jet fuel prices have nearly doubled since the U.S.-Israeli strikes on Iran disrupted the Strait of Hormuz. Fuel—typically about a quarter of an airline's operating expenses—has become an anchor dragging down the entire operation.

And the forecast for the rest of the year is where the real pain lives.

American now expects to report full-year adjusted earnings per share somewhere between a loss of $0.40 and a profit of $1.10. That is a dramatic cut from the January forecast of $1.70 to $2.70 per share.

CEO Robert Isom tried to strike a balance between realism and reassurance. "We're going to recover, but key to that is just supply and demand balance," he told CNBC. And then came the warning that should make every traveler pay attention: "We're going to be quick to make sure that we adjust our flying if we need to".

In plain English: If things get worse, routes will disappear.

This is the story of how the Iran war reached your ticket price, how American is uniquely vulnerable to this crisis, and what happens next for the millions of Americans who rely on this airline to get them where they need to go.

## Part 1: The Numbers That Matter – A Record Revenue That Couldn't Save the Quarter

Let's start with the good news, because there is some.

Americans are still flying in record numbers. The airline pulled in $13.91 billion in revenue during the first quarter, a 10.8% jump from the same period last year and slightly better than Wall Street had anticipated. That is not a small feat. In an environment where consumers are watching every dollar, demand for air travel has held remarkably steady.

The adjusted loss of $0.40 per share was actually narrower than the $0.47 loss analysts had braced for. And the net loss of $382 million, while painful, was an improvement over the $473 million loss from the year before.

So why the panic? Why the dramatic guidance cut?

Because airlines sell tickets months in advance. When the Iran war erupted on February 28, most of American's spring tickets had already been sold at pre-war prices. The airline absorbed the fuel spike for those flights directly, eating the difference between what it budgeted for fuel and what fuel actually cost.

That dynamic is now reversing. For summer and fall travel, airlines are raising fares—but they are also competing for passengers who are increasingly price-sensitive. The question is whether the revenue increases can keep pace with the fuel increases.

So far, the answer is no. American now expects its full-year fuel bill to climb by more than $4 billion compared to prior expectations. That is more than half the company's entire market capitalization of approximately $7.6 billion.

Let that sink in. The increase in American's fuel costs alone is worth more than half of what the entire company is valued at on the stock market.

## Part 2: The Iran War Connection – Why a Conflict 7,000 Miles Away Hits Your Wallet

You might be wondering: Why is a war in the Middle East affecting an airline based in Fort Worth, Texas?

The answer is a 21-mile-wide waterway called the **Strait of Hormuz**.

Before the war, approximately 20% of the world's petroleum flowed through this narrow channel between Oman and Iran. When U.S.-Israeli strikes targeted Iranian installations on February 28, Iran retaliated by restricting traffic through the strait. The U.S. responded with a naval blockade.

The result? Global oil supplies tightened almost immediately. Jet fuel prices—already elevated—nearly doubled.

Here is the cruel math for airlines: Fuel is typically about a quarter of operating expenses. When that cost doubles, the entire financial model strains. And unlike other industries that can adjust prices instantly, airlines sell tickets months in advance. They were locked into pre-war fares while paying post-war fuel prices.

American is not alone in this struggle, but it is uniquely exposed. Unlike Delta and United, which maintain sophisticated fuel-hedging programs to lock in prices in advance, American has historically operated without a comprehensive hedging strategy.

When prices are falling, that approach looks savvy. When prices spike due to a geopolitical crisis, it looks catastrophic.

## Part 3: The Debt Dilemma – Why American Is More Fragile Than Its Rivals

Fuel is not the only problem. American is also carrying more debt than its competitors.

The airline ended the first quarter with total debt of $34.7 billion. That is actually the lowest level since mid-2015, representing progress. But it is still a massive burden when margins are being squeezed from every direction.

The company has negative shareholders' equity of approximately $3.7 billion. In plain English, that means its liabilities exceed its assets. It is not a death sentence—many airlines have operated with negative equity for years. But it does mean the margin for error is razor-thin.

Compare this to Delta or United. Both have stronger balance sheets, more robust hedging programs, and more diversified revenue streams. When fuel spikes, they have cushions. American has less padding.

This is why the fuel crisis cuts so deep. Every dollar of unexpected fuel expense goes straight to the bottom line, eroding whatever profit might have existed.

The airline still has liquidity—$10.8 billion in cash and short-term investments as of March 31. That provides a buffer. But that buffer is being drawn down with every expensive gallon of jet fuel.

## Part 4: The Summer Outlook – What This Means for Your Travel Plans

So what does all of this mean for the person trying to book a summer vacation?

**Expect higher fares.** Airlines are already raising ticket prices to offset fuel costs. American has signaled it will "adjust flying" if demand softens. That is airline code for canceling routes, reducing flight frequencies, and grounding planes.

**Expect fewer last-minute deals.** The days of scoring a bargain flight a week before departure are likely over for the foreseeable future. Airlines have less capacity to fill and less incentive to discount when fuel costs are high.

**Expect more fees.** American raised its second-checked-bag fee from $45 to $50 for bookings made after February 18, 2026. The industry is watching to see whether this trend continues. When airlines cannot raise base fares enough, they turn to ancillary revenue—bag fees, seat selection fees, priority boarding fees.

The airline's second-quarter guidance reflects this tension. American expects revenue to grow 13.5% to 16.5% compared to the same period last year. That is strong growth. But earnings are expected to range from a loss of $0.20 per share to a profit of $0.20 per share. The midpoint of zero falls short of analyst expectations.

In other words: More money is coming in, but even more money is going out to pay for fuel.

For passengers, this means one thing: book early, and be prepared to pay more than you did last year. The era of cheap summer flights—if it ever really existed—is on hiatus.

## Part 5: The Alaska Connection – A Potential Lifeline in Turbulent Skies

Amid all the bad news, there is one development that has analysts cautiously optimistic.

American is in preliminary talks with **Alaska Air Group** to deepen international cooperation. This would not be a merger. It would be a revenue-sharing partnership—similar to the "metal-neutral" joint ventures that Delta has with Air France-KLM and Virgin Atlantic.

Why does this matter? Because it would give American access to routes and markets it does not currently serve, while giving Alaska access to American's extensive global network.

For American, the benefit is clear. It can expand its international footprint without spending billions on new aircraft or fighting for scarce landing slots at congested airports. For Alaska, the deal would provide a lifeline to international markets it cannot reach on its own.

The talks are described as "preliminary," and no deal has been announced. But the mere fact that American is exploring creative partnerships suggests management recognizes that the fuel crisis requires unconventional solutions.

**The Merger That Wasn't**

Just weeks ago, merger speculation was swirling around American. United Airlines CEO Scott Kirby reportedly proposed a combination during a meeting at the White House. The idea was simple: scale helps manage costs. A merged American-United would control roughly 30% of domestic air traffic, giving it pricing power and operational efficiencies that neither airline possesses alone.

American publicly rejected the overture. CEO Robert Isom stated that a combination would be "negative for competition and inconsistent with antitrust principles". President Trump also voiced opposition, effectively killing any near-term momentum for a deal.

The failed merger speculation briefly lifted American's shares before the rejection sent them back down. Without a takeover premium, the stock has to stand on its own merits. And those merits are currently being tested by $4.00-per-gallon jet fuel.

## FAQ: Your Questions About American Airlines Answered

**Q: How bad was American's first quarter, really?**

A: It was mixed. Revenue hit a record $13.91 billion, and the adjusted loss of $0.40 per share was actually better than Wall Street's $0.47 loss estimate. But the net loss of $382 million, combined with the dramatic guidance cut for the rest of the year, painted a picture of a company under significant stress.

**Q: Why did American cut its 2026 earnings forecast so dramatically?**

A: Jet fuel prices have nearly doubled since the Iran war began in late February. American now expects its fuel bill to increase by more than $4 billion for the full year compared to prior expectations. The new guidance range—a loss of $0.40 to a profit of $1.10 per share—reflects that crushing reality.

**Q: Is American Airlines at risk of bankruptcy?**

A: Not imminently. The airline has $10.8 billion in liquidity and has been reducing its debt load, which is now at its lowest level since 2015. However, the company has negative shareholders' equity of approximately $3.7 billion, meaning its liabilities exceed its assets. A prolonged fuel crisis would put significant strain on the airline.

**Q: What is the Alaska Airlines partnership about?**

A: American is in preliminary talks with Alaska Air to deepen international cooperation. The potential agreement would be a revenue-sharing partnership, allowing both carriers to coordinate schedules and share revenue on certain routes without a full merger.

**Q: Did American almost merge with United?**

A: United CEO Scott Kirby proposed a merger during a White House meeting, but American publicly rejected the idea. CEO Robert Isom stated a combination would be "negative for competition," and President Trump also voiced opposition.

**Q: How will this affect my summer travel plans?**

A: Expect higher fares and potentially fewer flight options. Airlines are raising prices to offset fuel costs, and American has signaled it may "adjust flying" if demand softens. Book early, and be prepared to pay more than you did last year.

**Q: What is the analyst consensus on American Airlines stock?**

A: The consensus rating is "Hold" with an average price target of $15.09. UBS recently raised its target to $16 with a "buy" rating, while Jefferies cut its target to $12 with a "hold". The split reflects uncertainty about whether the fuel crisis will be temporary or prolonged.

**Q: Did American raise its baggage fees?**

A: Yes. For bookings made after February 18, 2026, American increased the fee for a second checked bag from $45 to $50 when paid at the airport. The first checked bag fee remains $35 for online payment and $40 at the airport. Prepaying online avoids the increase.

## Conclusion: The Long Runway Ahead

American Airlines just reported a quarter that defies easy characterization. Record revenue. A narrower-than-expected loss. And a forecast that suggests the rest of the year will be a white-knuckle ride.

The fuel crisis is real. The $4 billion hit is real. And the structural vulnerabilities that make American more exposed than its rivals are not going away.

But neither is the demand. People still need to fly. Businesses still need to move employees. Families still need to see each other. That fundamental reality is what keeps American in the air.

CEO Robert Isom said the airline will recover. He is probably right. The question is when—and what the airline looks like on the other side.

For travelers, the message is clear: book early, expect higher prices, and stay flexible. For investors, the calculus is more complicated. The stock is cheap for a reason. The risks are real. But so is the potential reward if fuel prices retreat.

For everyone else, American's earnings are a window into the broader economy. When jet fuel spikes, everything gets more expensive. The goods on store shelves. The food in grocery stores. The tickets to see family across the country.

The Iran war is 7,000 miles away. But its economic shockwaves are landing right here, on the tarmac at DFW, at the ticket counter in LaGuardia, and in the bank accounts of millions of Americans.

Buckle up. It is going to be a turbulent summer.

---

**#AmericanAirlines #AALStock #JetFuel #IranWar #AirlineIndustry #EarningsSeason #Investing #Travel**

---

*Disclaimer: This article is for informational purposes only. It does not constitute financial or investment advice. Fuel prices, geopolitical situations, and airline earnings are subject to rapid change. Always consult a licensed professional before making investment decisions.*

The $110 Billion Showdown: Warner Bros. Discovery Shareholders Vote Today on Paramount’s Hollywood Takeover

The $110 Billion Showdown: Warner Bros. Discovery Shareholders Vote Today on Paramount’s Hollywood Takeover

**Subtitle:** *After a brutal bidding war with Netflix, David Ellison’s Paramount Skydance is one step away from owning Harry Potter, Batman, and CNN. But with David Zaslav’s $800 million “golden parachute” and a looming political firestorm, is this the deal that saves Hollywood—or kills it?*

**Reading Time:** 8 Minutes | **Category:** Business & Entertainment

## Introduction: The Day Hollywood Held Its Breath

At 10:00 AM Eastern Time on Thursday, April 23, 2026, a group of shareholders gathered—virtually and in person—to decide the fate of one of the last great American entertainment empires .

The question on the ballot: Should Warner Bros. Discovery, the $81 billion home of Harry Potter, Batman, Game of Thrones, HBO, and CNN, sell itself to Paramount Skydance, the upstart media company controlled by Oracle billionaire Larry Ellison and his son, David? 

By the time the polls close, one of the most dramatic takeover battles in Hollywood history could be all but over.

But do not be fooled by the quiet of the boardroom. This vote is not just about spreadsheets and share prices. It is about the future of the films you watch, the streaming bills you pay, and the news you hear.

It is about whether CNN can survive the Trump era under new ownership that is openly cozy with the White House. It is about whether a new media giant—one that rivals Netflix—can be built from the ashes of cable television. And it is about the money: specifically, the **$800 million** payout awaiting Warner Bros. Discovery CEO David Zaslav if he successfully sells the company .

In this deep-dive, we will walk you through the vote, the astonishing bidding war that pitted Paramount against Netflix, and the "Golden Parachute" controversy that has even the deal’s supporters holding their noses. We will also break down the three ways this merger changes your living room, and the two major hurdles (spoiler: one involves Saudi oil money) that could still blow the deal up.

Because here is the truth: The merger isn't done yet. The shareholders vote today, but the real fights happen tomorrow. The outcome will define the entertainment landscape for the next decade.

## Part 1: The Vote – What Shareholders Are Deciding (And Why They Will Probably Say Yes)

If you own Warner Bros. Discovery stock (ticker: WBD), today is the day you cash out—or double down.

### The Deal: $110 Billion for the Whole Package

Technically, Paramount Skydance Corporation is offering **$31.00 per share in cash** for every share of Warner Bros. Discovery . This values the equity of the company at approximately **$81 billion**.

But digging deeper: Paramount is also taking on Warner’s massive debt load. When you add that in, the total transaction value balloons to a staggering **$110 billion** .

**The Premium:** For long-suffering WBD shareholders, this is a life raft. Just a year ago, following the disastrous merger of WarnerMedia and Discovery, the stock was trading at a miserable **$8 per share** . The $31 offer represents a nearly 400% premium on that price.

**The Recommendation:** The top proxy advisory firm, Institutional Shareholder Services (ISS), has told investors to vote "Yes" . ISS argued that the shareholders are getting a "meaningful premium" and that the "downside risk of non-approval" is simply too high.

### The Golden Parachute: The $800 Million Question

Here is the part that is making investors squirm.

If the deal goes through, WBD CEO **David Zaslav** stands to receive a severance package worth an estimated **$800 million** or more .

ISS is notably *not* endorsing this payout. In fact, they are telling shareholders to vote *against* the **"golden parachute"** compensation, even if they vote *for* the merger itself .

The package includes hundreds of millions in stock awards and a "gross-up" for the excise tax on these golden parachutes—a loophole allowing executives to be reimbursed for the taxes the government intended to punish them with.

For the rank-and-file employees of Warner Bros.—the writers, the editors, the production assistants—who may be facing layoffs in the coming months , watching the CEO walk away with nearly a billion dollars is going to sting.

**The Human Touch:** This is the duality of Wall Street. The shareholder vote is about maximizing return. But for the thousands of workers at the Warner Bros. lot in Burbank and the HBO offices in New York, this vote is about job security. The math is simple: When two studios become one, someone gets fired.

## Part 2: The Bidding War – How Paramount Beat Netflix

This vote wasn't supposed to happen. Just a few months ago, David Zaslav had a different dance partner.

### The Netflix "Plan B"

Late last year, Warner Bros. had rebuffed Paramount’s initial overtures. Instead, they struck a **$72 billion deal** with Netflix to sell off the studio and the streaming assets .

Why? Zaslav was trying to dump the "legacy baggage." He wanted to get rid of the declining cable channels (CNN, TNT, Discovery) but keep the lucrative streaming future. Netflix was happy to buy the content factory, but they didn't want the cable headache.

### The Hostile Turn

But Paramount wanted *all* of Warner. And when they got angry, they got aggressive .

Paramount went directly to the shareholders with a **hostile tender offer**—essentially saying: *"Your board doesn't want to sell the whole company, but we are offering you so much cash that you will force them to."*

Netflix tried to counter. For months, the three companies slung mud. But in late February, Netflix blinked .

**Netflix co-CEO Ted Sarandos** walked away, calling Paramount an "irrational" bidder that was willing to overpay to win at all costs . Netflix collected a massive **$2.8 billion breakup fee** from Warner Bros., which Paramount—desperate to close the deal—agreed to cover .

Thus, the path was cleared for today's vote.

## Part 3: The Three Ways This Changes Your Living Room

Let’s put aside the corporate jargon for a moment. What does this mean for you, the consumer?

### 1. The Streaming Merger (HBO Max + Paramount+)

Currently, you probably pay for several streaming services. After the merger, you may be paying for one less—or paying more for the one that remains .

Paramount executives argue that combining HBO Max and Paramount+ will create a "super-bundle" with a massive content library. Imagine: *Dune* next to *Top Gun*, *The White Lotus* next to *Yellowstone*, *Harry Potter* next to *SpongeBob*.

**The Risk:** Critics, including New York City Mayor Zohran Mamdani, argue this is terrible for consumers. "Streaming bills going up as competition disappears," Mamdani warned . When giants merge, the price of the subscription rarely goes down.

### 2. The News Shake-Up (CNN + CBS)

This is the political hot potato.

Since the Ellison family took over Paramount less than a year ago, CBS News has already seen a dramatic editorial shift. They installed **Bari Weiss**, founder of The Free Press, as editor-in-chief—a move seen as a sharp pivot toward centrist/independent media .

Now, imagine that playbook applied to **CNN**.

President Trump has a famously adversarial relationship with CNN. However, David Ellison’s father, **Larry Ellison**, is a close ally of President Trump and is financing this deal . Furthermore, Paramount is hosting a glitzy dinner at the White House Correspondents' Association weekend (as the shareholders vote) in Trump's honor .

Critics fear that a combined CNN/CBS under the Ellison umbrella will pull punches on covering the administration. Supporters argue CNN needs to be "saved" from its bias.

### 3. The Theatrical Experience (30 Movies a Year)

David Ellison, a film producer at heart, has made a bold promise to Hollywood .

He has guaranteed a **45-day theatrical window** (meaning movies won't immediately dump to streaming). He has pledged that Paramount and Warner will remain "stand-alone" operations, pumping out a combined **30 movies a year** for the big screen .

If he keeps that promise, movie theaters—which have been dying a slow death—may survive a little longer.

**The Human Touch:** For the actor worried about their residuals, or the director terrified of losing their distribution deal to AI, Ellison is selling himself as the "Rich Savior of Cinema." But the fine print reveals he will also be looking to cut "overlapping operations"—which is code for mass layoffs .

## Part 4: The Two Hurdles (The Fight Isn't Over)

Even if the shareholders vote "Yes" at 10:00 AM, the deal is not done. It has to run a gauntlet.

### Hurdle 1: The Saudi Money (The National Security Angle)

Where is David Ellison getting his cash? From his dad (Oracle's Larry) and from **sovereign wealth funds in Saudi Arabia, the UAE, and Qatar** .

This is a major red flag. The U.S. government has to approve a sale that puts American media assets—specifically CNN, a major propaganda tool for the free world—partially backed by foreign governments known for human rights abuses.

**The Defense:** Paramount has filed paperwork insisting these foreign funds will have **no governance rights** and will be pure passive investors . But will that fly with the DOJ?

### Hurdle 2: The Regulators (DoJ and the States)

Democratic Senator Cory Booker held a "spotlight" hearing last week, arguing that this is not just a business deal—it is a concentration of "cultural power" .

California Attorney General **Rob Bonta** has said his state is actively investigating the merger . A coalition of Democratic AGs successfully killed a similar media merger recently (Nexstar/Tegna) and are eyeing this one.

**The "Ticking Fee":** To keep the deal moving, Paramount has included a "ticking fee" in the contract. If regulators delay the merger past September 30, the price Paramount pays for each share goes up . Translation: *"Please hurry up and approve this."*

## Keyword Deep Dive: Profitable, Low Competition Niches

For publishers and content creators, the Paramount-WBD merger is a goldmine of **high CPC (Cost Per Click)** terms in the business and finance vertical.

| Keyword Category | Specific Phrase | Why It Pays |

| :--- | :--- | :--- |

| **Media Investing** | *"Warner Bros Discovery stock vote live updates"* | Day traders and investors tracking real-time results. CPC: $7-10 |

| **Executive Compensation** | *"David Zaslav golden parachute value 2026"* | High-intent search for the controversial $800M payout. CPC: $8-12 |

| **Political Intrigue** | *"Trump Ellison CNN merger influence 2026"* | News junkies and political analysts. CPC: $6-9 |

| **Streaming Strategy** | *"HBO Max Paramount Plus combined subscription price"* | Consumers trying to predict their bills. CPC: $4-6 |

| **Regulatory Risk** | * "Paramount Saudi sovereign wealth fund CNN approval"* | Legal and compliance professionals. CPC: $10-15 |

**Pro Tip:** The most profitable angle here is the **"CNN/Saudi"** link. It combines geopolitics, media law, and finance—an incredibly high-value niche with very little "noise" compared to the general movie news.

## The Viral Spread Strategy

To make this story go viral, you have to focus on the outrage and the spectacle.

**Angle #1: "The $800 Million Man"**

David Zaslav is the villain or the hero depending on your view. A graphic comparing the CEO's payout to the number of junior writer salaries it could pay (Spoiler: thousands) is highly shareable on LinkedIn and X.

**Angle #2: "The List"**

Create a visual graphic listing every franchise that will be under one roof: *Batman, Harry Potter, Lord of the Rings, Game of Thrones, South Park, SpongeBob, Mission: Impossible, Top Gun, Jurassic World.* That sheer list of Intellectual Property is mind-boggling and photographic.

**Angle #3: "The Hostile Takeover"**

A timeline from September 2025 to April 2026 showing the "Three-Way War" (Paramount vs. Netflix vs. WBD). Business audiences love timeline deep-dives.

**Angle #4: "MSNBC vs. Fox News 2.0"**

With CNN likely pivoting to the center/right under Ellison, the media narrative is shifting. This is meta-content that media critics will eat up.

## Frequently Asked Questions (FAQ)

**Q: When is the Warner Bros. Discovery shareholder vote?**

**A:** The vote is scheduled for **Thursday, April 23, 2026, at 10:00 AM Eastern Time** .

**Q: What is the price Paramount is paying for Warner Bros. Discovery?**

**A:** Paramount will pay **$31.00 per share in cash**. This values the equity at $81 billion, but with debt included, the total enterprise value is approximately **$110 billion** .

**Q: Who wins if the deal goes through?**

**A:** Shareholders win because they get a premium. David Ellison wins because he becomes a media mogul. **David Zaslav** wins because he gets an estimated **$800 million+ payout** if he leaves . However, many employees may lose their jobs due to overlapping operations .

**Q: Is Netflix involved in this deal?**

**A:** No. Netflix was fighting to buy Warner's studio and streaming assets, but Paramount swooped in with a hostile bid for the entire company. Netflix walked away (but collected a **$2.8 billion** breakup fee from Warner, which Paramount is paying) .

**Q: Will CNN change under the Ellisons?**

**A:** Almost certainly. When the Ellisons took over Paramount-owned CBS, they installed right-leaning indie journalist Bari Weiss as editor. Many expect a similar "editorial pivot" at CNN to avoid the ire of President Trump, who has close ties to Ellison .

**Q: What are the chances this deal gets blocked?**

**A:** Higher than usual. There is opposition from Democratic Senators (Booker) and State AGs (California), and there is concern about the involvement of the **Saudi Arabian Public Investment Fund** in the financing .

**Q: What is a "golden parachute"?**

**A:** It is a large sum of money guaranteed to a CEO if they are let go after a merger. In this case, **David Zaslav** is entitled to one. Proxy advisory firm ISS has told shareholders to reject the specific payout, even if they accept the merger .

## Conclusion: The Empire Strikes... Cash

We started this article with a vote count. We end with a reality check.

The $110 billion sale of Warner Bros. Discovery to Paramount Skydance is the most significant media merger since the creation of AOL Time Warner (which, ironically, was the greatest disaster in media history).

If the shareholders approve it today, we move into the regulatory phase. The deal will live or die based on whether the Biden/Trump administration (depending on who is truly pulling the strings) lets Saudi money touch CNN, and whether Hollywood unions can convince the DOJ that "Too Big To Fail" applies to storytelling.

**For the Investor:**

Take the $31. It is a good exit. The media landscape is cratering, and cash is king.

**For the Movie Fan:**

You might get better superhero movies. You will probably pay more for streaming. HBO and Paramount are likely merging into one app.

**For the News Watcher:**

Get ready for a new era. CNN is about to be Orange-tinted. The line between "News" and "Commentary" is about to get even blurrier.

**For the Content Creator:**

The drama is just beginning. The layoffs, the lawsuits, and the culture war are the next chapters. Stay tuned.

**The Bottom Line:**

The vote is just the opening scene. The real movie—whatever it is—starts rolling as soon as the gavel drops.

---

**#WarnerBros #Paramount #DavidZaslav #Hollywood #Merger #CNN #Streaming #MediaNews**

---

*Disclaimer: This article is for informational purposes only. It does not constitute financial or investment advice. Stock mergers are subject to regulatory approval and can be blocked or delayed.*

The Green Light: Trump Reclassifies State-Licensed Medical Marijuana in Historic Rescheduling Victory

 

 The Green Light: Trump Reclassifies State-Licensed Medical Marijuana in Historic Rescheduling Victory

**Subtitle:** *Acting Attorney General Todd Blanche signed the order April 23, moving cannabis from Schedule I (heroin territory) to Schedule III (Tylenol with codeine). Here is what the 280E tax windfall, the banking breakthrough, and the looming DEA hearing mean for patients, businesses, and your portfolio.*

**Reading Time:** 8 Minutes | **Category:** Politics & Economy

## Introduction: The 60-Year Wall Just Cracked

For nearly six decades, the federal government has treated medical marijuana with the same severity as heroin. Under the Controlled Substances Act, cannabis sat straight in **Schedule I** —the highest restriction level—defined by the Drug Enforcement Administration as substances with "no accepted medical use and a high potential for abuse" .

That classification placed marijuana alongside LSD, ecstasy, and the most dangerous narcotics. It made every state-legal dispensary a federal crime scene. It barred researchers from studying the drug's effects. And it forced small business owners to pay effective tax rates of 70 to 90 percent .

On Thursday, April 23, 2026, that wall developed a massive crack.

Acting Attorney General Todd Blanche signed an official order reclassifying **state-licensed medical marijuana products** from Schedule I to **Schedule III** —the same category as Tylenol with codeine, ketamine, and anabolic steroids .

President Donald Trump, who first ordered the rescheduling process in December, has delivered what advocates have sought for decades. "This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information," Blanche said in a statement .

The order does not legalize recreational marijuana at the federal level. It does not erase the sentences of those incarcerated for possession. But it fundamentally alters the legal and economic landscape for medical cannabis in America.

In this deep-dive, we will break down exactly what changed, walk through the explosive **Section 280E tax relief** that could save the industry billions, and explain why the stock market reacted with a 28 percent surge in cannabis equities. We will also answer the questions every American patient, business owner, and investor is asking: Can I deduct my rent now? Will banks finally accept my deposits? And what happens when the DEA holds its hearing in late June?

Because here is the truth: The rescheduling wars are not over. The critics are mobilizing. And the final outcome depends on a federal judge, a DEA administrative law judge, and the outcome of a hearing scheduled for June 29, 2026 .

## Part 1: The Schedule I to Schedule III Leap – What the Order Actually Does

Let us start with the plain language of the law. The Controlled Substances Act organizes drugs into five "schedules" based on medical use and abuse potential.

### The Old Reality: Schedule I

| Schedule | Definition | Examples |

| :--- | :--- | :--- |

| **I** | No accepted medical use, high potential for abuse | Heroin, LSD, ecstasy, **marijuana** |

| **II** | Some medical use, high abuse potential | Cocaine, methamphetamine, oxycodone |

| **III** | Accepted medical use, moderate to low abuse potential | Tylenol with codeine, ketamine, anabolic steroids |

Under Schedule I, the federal government argued that cannabis had no medical value whatsoever. Every state-licensed dispensary—even those operating perfectly within their state laws—was theoretically engaged in federal drug trafficking.

### The New Reality: Schedule III

Blanche's order changes that calculation.

**The Legal Shift:** Under the new order, any marijuana product that is either (1) approved by the Food and Drug Administration or (2) distributed through a **state-licensed medical marijuana program** is now classified as Schedule III .

**What This Means:**

- The federal government acknowledges that marijuana has **accepted medical uses**.

- Researchers can obtain state-licensed marijuana for studies without federal penalty.

- The Internal Revenue Code Section 280E—which bars businesses "trafficking" in Schedule I or II substances from deducting ordinary expenses—**no longer applies** to state-licensed medical cannabis operators .

**What This Does Not Mean:**

- Recreational marijuana remains fully illegal under federal law.

- State-licensed recreational dispensaries (selling to adults without medical cards) may still face 280E unless they also hold medical licenses.

- Banking access is not guaranteed—though the reduced federal compliance risk may encourage more financial institutions to enter the space .

### The "Two-Track" System

The Justice Department used a clever legal maneuver to sidestep the lengthy rulemaking process that had stalled under President Biden. Instead of waiting for the DEA to complete a full notice-and-comment rulemaking, Blanche invoked a provision of federal law that allows the attorney general to determine appropriate classifications for drugs regulated pursuant to an **international treaty** .

The result is a two-track system moving forward simultaneously:

| Track | Description | Timeline |

| :--- | :--- | :--- |

| **Medical Marijuana (State-Licensed)** | Reclassified to Schedule III via AG order | Effective 30 days after publication in Federal Register |

| **All Marijuana (Broad Rescheduling)** | Subject to DEA administrative hearing | Hearing scheduled for June 29, 2026 |

The broader rescheduling—which would apply to all marijuana, not just state-licensed medical products—will be debated before a DEA administrative law judge in late June . That hearing could lead to a final rule covering the entire industry.

**The Human Touch:** For the cancer patient using medical marijuana to manage chemotherapy-induced nausea, the rescheduling is validation. The federal government finally agrees with what their doctor told them: this substance has medical value. For the dispensary owner who has spent years paying taxes at 80 percent effective rates, the change is survival.

## Part 2: The 280E Windfall – Billions in Tax Relief Finally Arrives

If there is one sentence that will make every cannabis business owner cry tears of relief, it is this: **Section 280E no longer applies to state-licensed medical marijuana operators**.

### What Is Section 280E?

Passed in 1982 at the height of the War on Drugs, Internal Revenue Code Section 280E prohibits businesses engaged in "trafficking" in Schedule I or II controlled substances from deducting ordinary business expenses .

For normal businesses, deductions are simple: you subtract your rent, payroll, marketing, utilities, and other operating costs from your revenue, then pay taxes on the profit.

For cannabis businesses under Schedule I, 280E meant they could deduct the **cost of goods sold** (the direct cost of the product itself) but **nothing else**. Rent? Not deductible. Employee salaries? Not deductible. Marketing? Not deductible. Security systems? Not deductible.

**The Result:** Effective tax rates of 70 to 90 percent, according to industry estimates . Some operators paid more in taxes than they earned in profit.

### The Numbers

According to an analysis by Whitney Economics released earlier this month, cannabis businesses have paid an estimated **$15 billion in excess 280E-related taxes** since 2018 .

Under Schedule III, that burden evaporates—at least for the medical side of the business.

Brian Vicente, a founding partner of Vicente LLP, a Denver-based cannabis law firm, explained the magnitude: "We're talking about billions of dollars in new economic activity, tens of thousands of new jobs, or just really a wind in the sail for this industry that's really paid a very heavy tax burden for years" .

**The Immediate Impact:** State-licensed medical marijuana operators can now deduct:

- Rent and lease payments

- Employee wages and benefits

- Marketing and advertising costs

- Security system expenses

- Utilities and office supplies

- Professional services (legal, accounting)

### The 280E "Trap" for Mixed Operators

Here is where it gets complicated. Many dispensaries serve both medical patients and recreational adult-use customers under the same roof.

The order from Blanche applies specifically to **state-licensed medical marijuana products** and the operators distributing them . It is not yet clear how the IRS will handle a dispensary that sells both medical and recreational products.

**The Conservative Interpretation:** The portion of revenue attributable to medical sales is protected from 280E. The portion attributable to recreational sales is not.

**The Aggressive Interpretation:** Some tax attorneys argue that the entire operation should qualify, since the business holds a state medical license. But this is unsettled territory—and likely headed for tax court .

### The Retroactive Question

Can businesses file amended returns for previous years and claim refunds?

Almost certainly not.

As Rachel Gillette, a Denver-based tax attorney, explained: "That's the official position of the IRS" . The agency has generally never allowed retroactive amendments based on changes in the law. Some operators may try, but they should expect a fight.

**The Human Touch:** For the dispensary owner who has struggled to stay afloat despite booming sales, the 280E relief is not abstract. It is the difference between reinvesting in their business and watching it crumble. It is hiring two more budtenders versus laying off half the staff. It is real. It is immediate. And it is long overdue.

## Part 3: The Market Reacts – Cannabis Stocks Surge Over 28 Percent

Wall Street saw the news before most of America woke up.

### The Axios Report Triggers a Stampede

On Wednesday, April 22, Axios reported that the Trump administration was preparing to reclassify marijuana . The news spread like wildfire through trading desks.

By the closing bell, the numbers were extraordinary.

| Stock | Daily Gain | Key Context |

| :--- | :--- | :--- |

| **Curaleaf Holdings (CURLF)** | +28.07% | U.S. multi-state operator, heavy medical focus |

| **Canopy Growth (CGC)** | +18.42% | Canadian giant, U.S. expansion via acquisitions |

| **Tilray Brands (TLRY)** | +10.81% | Volume exceeded 8x daily average |

| **Aurora Cannabis (ACB)** | +7.4% | Canadian medical-focused producer |

| **AdvisorShares Pure US Cannabis ETF (MSOS)** | +19.51% | Broad industry benchmark |

The moves were not just percentage spikes; they were volume explosions. Tilray's trading volume exceeded its daily average by more than eight times .

### The Broader Market Context

The S&P 500 closed up 0.78 percent on the same day, while the VIX volatility index fell 2.21 percent to 19.07 . The broader market was already in a positive mood, but cannabis stocks dramatically outpaced the indices.

### The "Trump Trade" Returns

Cannabis stocks have been an abysmal investment for years. Many of the highest-profile names—Tilray, Canopy, Aurora—went public to great fanfare in 2018, only to lose 90 to 99 percent of their value over the following half-decade .

The reclassification news has reignited interest in the sector. As Matt Karnes, founder of cannabis financial analysis firm GreenWave Advisors, noted: "The reclassification to Schedule III will have a material impact on the valuation of cannabis stocks" .

### The Cautious View

Not everyone is buying the hype.

Canadian multi-state operators still face significant headwinds. The U.S. cannabis market remains fragmented by state lines. Interstate commerce is still prohibited. And the DEA hearing in June could still derail or delay the broader rescheduling.

One analyst quoted in the Daily Mail put it bluntly: "Even among beaten-down marijuana stocks, this company [Tilray] has been an astonishing disappointment and a huge underperformer" .

**The Human Touch:** For the retail investor who bought Tilray at its 2018 peak of $300 per share (split-adjusted), today's $10 price is cold comfort. But for the investor who bought three months ago on rumors of rescheduling, the 28 percent gain is a very nice day at the office.

## Part 4: The Banking Breakthrough – Will the Doors Finally Open?

One of the most persistent complaints from cannabis business owners is the **banking problem**. Because marijuana remains illegal at the federal level, most major banks refuse to accept deposits or extend credit to cannabis businesses.

### The Current Reality

Currently, most cannabis businesses operate on a cash-only basis. Payroll is paid in cash. Taxes are paid in cash. Vendors are paid in cash. The security risks are enormous, and the administrative burden is crushing.

### The Schedule III Effect

Rescheduling does not automatically solve the banking problem. But it dramatically reduces the risk.

Under Schedule I, banks that serviced cannabis businesses were potentially engaging in **money laundering** under federal law—aiding and abetting the distribution of a Schedule I controlled substance.

Under Schedule III, the calculus changes. As Brian Vicente explained: "While this would not change the legality of cannabis, it would move it to Schedule III, which would help fast-track research and certainly reduce some of the stigma attached to this medicine" .

**The Practical Impact:** State-chartered banks and credit unions may be more willing to enter the space. The SAFE Banking Act—legislation that would explicitly protect financial institutions serving state-legal cannabis businesses—still needs to pass Congress. But rescheduling makes that passage more likely.

### The Limitations

For now, cannabis businesses remain shut out of mainstream capital markets. They cannot list on the New York Stock Exchange or Nasdaq. They cannot access traditional venture capital or private equity at reasonable rates. They cannot even obtain a federal trademark for their brands .

Schedule III does not change these realities. Only an act of Congress can fully normalize the industry.

**The Human Touch:** For the dispensary owner counting stacks of $20 bills at 2:00 AM, worrying about robbery and audit trails, the banking problem is not an abstraction. It is the daily reality of running a business that the federal government still considers illegal—even if the new classification makes that illegality slightly less severe.

## Part 5: The Road Ahead – DEA Hearings, Legal Challenges, and Implementation

The signing of Blanche's order is a historic moment. But it is not the final moment.

### The 30-Day Countdown

Once the order is published in the Federal Register—likely within days—a **30-day clock** begins. After that period, the reclassification takes effect unless blocked by a court .

### The Legal Challenges

Opponents of marijuana rescheduling have already vowed to sue.

Kevin Sabet, chief executive of Smart Approaches to Marijuana, was characteristically blunt: "With this move, we are now confronted with the most pro-drug administration in our history. Policy is now being dictated by marijuana CEOs, psychedelics investors, and podcasters in active addiction" .

Sabet's group and others will almost certainly file for an injunction to block implementation. The case will likely land before a federal judge—potentially one appointed by Trump, ironically enough.

### The DEA Hearing (June 29, 2026)

Separate from the medical marijuana order, the broader rescheduling of all marijuana—including recreational—will be the subject of an administrative hearing before a DEA administrative law judge starting **June 29, 2026** .

That hearing will determine whether the across-the-board rescheduling first proposed under President Biden will finally be finalized. Witnesses will testify. Evidence will be presented. And the judge will issue a recommendation.

**The Timeline:** Even under the best-case scenario, with no legal challenges, the DEA process could take six months or more. With litigation, it could take years .

### The Hemp Amendment

One area that remains entirely unresolved is the regulatory status of **hemp-derived THC products**. Under the spending bill signed into law earlier this year, the federal definition of hemp will change in November 2026, making many popular hemp products illegal .

Trump's executive order directing the rescheduling of marijuana also instructed White House officials to "work with the Congress to update the statutory definition of final hemp-derived cannabinoid products" . But that is a request, not a mandate. Only Congress can act.

### The State-Level Impact

For the 40 states with medical marijuana programs and the 24 states (plus Washington, D.C.) with adult-use legalization, the Trump administration's order is largely legitimizing what already exists .

The order explicitly recognizes that state licensing frameworks have "demonstrated a sustained capacity to achieve the public-interest objectives ... including protecting public health and safety and preventing the diversion of controlled substances into illicit channels" .

**The Bottom Line:** State laws remain unchanged. If you are a medical marijuana patient in California, Colorado, or Florida, your access is unaffected—but your state-licensed dispensary just got a massive tax break.

**The Human Touch:** For the patient, the change is invisible but meaningful. The federal government now acknowledges that their medicine is real. For the operator, the change is visible in their bank account, their tax return, and their ability to sleep at night.

### End of Section

*Article continues in next section...*

## Frequently Asked Questions (FAQ)

**Q: Did Trump legalize marijuana?**

**A:** No. The order reclassifies **state-licensed medical marijuana** from Schedule I to Schedule III. Recreational marijuana remains fully illegal under federal law. Medical marijuana is still illegal at the federal level—just less strictly regulated .

**Q: What is the difference between Schedule I and Schedule III?**

**A:** Schedule I drugs are defined as having "no accepted medical use and a high potential for abuse." Schedule III drugs are defined as having "accepted medical use and a moderate to low potential for physical and psychological dependence" . Examples of Schedule III drugs include Tylenol with codeine, ketamine, and anabolic steroids.

**Q: Does this mean I can deduct my dispensary's rent on my taxes?**

**A:** If you operate a **state-licensed medical marijuana dispensary**, yes—assuming the IRS follows the plain language of the law. Section 280E, which previously barred deductions for Schedule I and II substances, does not apply to Schedule III substances . Mixed operators (medical + recreational) face more uncertainty.

**Q: Will my bank finally accept deposits from my cannabis business?**

**A:** Not necessarily. Rescheduling reduces federal compliance risk, which may encourage state-chartered banks and credit unions to enter the space. However, major national banks are likely to wait for explicit legislation (like the SAFE Banking Act) or further federal guidance .

**Q: When does this go into effect?**

**A:** The order takes effect **30 days after publication in the Federal Register**. Legal challenges are expected, which could delay implementation .

**Q: What happens at the DEA hearing in June?**

**A:** On **June 29, 2026**, the DEA will begin an administrative hearing to consider the broader rescheduling of all marijuana (not just state-licensed medical products). That hearing could lead to a final rule covering the entire industry—or it could result in further delays .

**Q: Does this affect my state's recreational dispensaries?**

**A:** Not directly. Recreational dispensaries that do not also hold medical licenses remain fully subject to Section 280E and other federal restrictions. However, many recreational dispensaries also serve medical patients—those portions of their business may now qualify for tax relief .

**Q: Can I grow my own medical marijuana at home under this order?**

**A:** No. The order applies to **state-licensed medical marijuana products** distributed through state-regulated channels. Home cultivation remains subject to state law—and federally, homegrown marijuana is not "state-licensed" and thus remains Schedule I .

## Conclusion: A Historic Crack, Not a Broken Door

We started this article with a wall—six decades of federal prohibition that treated medical marijuana with the same severity as heroin. We end with a crack.

Acting Attorney General Todd Blanche signed the order. President Trump delivered on his December promise. State-licensed medical marijuana is now Schedule III—a classification that acknowledges what patients and doctors have known for years: this substance has medical value.

The Section 280E tax relief is transformative for the industry. Billions of dollars in deductions will flow to businesses that have been operating with one hand tied behind their backs. The banking door has cracked open. The research barriers have been lowered.

But the door is not broken. Recreational marijuana remains fully illegal. The DEA hearing in June will determine the broader fate of rescheduling. Legal challenges are coming. And the IRS has not yet issued guidance on how mixed operators should file.

**For the Medical Marijuana Patient:**

Your medicine is now federally recognized as having medical value. That validation matters—psychologically and practically. Your state-licensed dispensary will have more resources to invest in quality, safety, and accessibility.

**For the Cannabis Business Owner:**

If you hold a state medical license, call your tax advisor immediately. The 280E deductions are real. But be cautious about filing amended returns for prior years—that path leads to tax court. And watch the DEA hearing closely; your entire operation may be affected by the outcome.

**For the Investor:**

The 28 percent surge in cannabis stocks reflects genuine optimism—and genuine relief. But the sector remains volatile. Legal challenges could reverse gains overnight. The DEA hearing could produce unfavorable results. And the broader market for recreational cannabis remains federally illegal. Proceed with eyes wide open.

**For the Content Creator:**

The rescheduling story is far from over. The DEA hearing, the legal challenges, the IRS guidance, and the state-by-state implementation will generate news for months. Write the explainers. Track the court cases. Follow the money. The audience for cannabis policy coverage is large, engaged, and hungry for clarity.

**The Bottom Line:**

Trump reclassified state-licensed medical marijuana as a less-dangerous drug. It is a historic shift—the most significant change in federal cannabis policy in six decades.

But it is not the finish line. It is the starting gun.

The DEA hearing begins June 29. The legal challenges will follow. And the cannabis industry—patients, operators, investors, and advocates alike—will spend the next year fighting for the next crack in the wall.

One thing is certain: the wall is no longer intact. And once the cracks appear, the light begins to shine through.

---

**#Trump #MarijuanaRescheduling #ScheduleIII #MedicalMarijuana #CannabisIndustry #280E #DEA #PotStocks**

---

*Disclaimer: This article is for informational purposes only and does not constitute legal or tax advice. The reclassification order is subject to legal challenge and DEA administrative proceedings. Always consult a licensed attorney or tax professional before making decisions based on changes in federal law.*